News

The commencement of the study trigered a $30m milestone payment to Threshold Pharmaceuticals from Merck under a license and co-development agreement signed between the companies. Randomized, placebo-controlled Phase

In the double-blind study, 845 patients were administered with Folfox or Folfiri and bevacizumab as the front-line treatment of locally-advanced or metastatic colorectal cancer. Neulasta demonstrated the significant

Each of the double-blind Phase 3 trials will randomize 840 HIV-1 infected patients containing a viral load of 1,000 copies/mL or more with a once-daily tablet containing TAF

The partnership aims to develop, improve and embed bioprocesses in order to facilitate the delivery of novel products for Almac’s biocatalysis business. Under the completion of Knowledge Transfer

Biocompatible, non-toxic remoldable synthetic antimicrobial hydrogel was developed to break diseased biofilms and eliminate drug-resistant bacteria. The hydrogel containong over 90% of water can be applied on hospital

Eeva test has been designed to improve the vitro fertilization (IVF) outcomes by assessing the viability of the embryo. The test measures various cell-division parameters, which are scientifically

The grant, entitled ‘Circulating Tumor Cell Enumeration Product’, will support the development and clinical validation of assay to detect and characterize circulating tumor cells (CTCs) in lung cancer

Response’s Flu A + B and RSV tests run on the RAMP 200 Reader diagnostic platform, which features multi-port capability to run up to 12 tests per hour

The endpoint of the parallel group study is a change from baseline in the 17-item Hamilton Rating Scale for Depression (HAM-D17) total score at the eighth week. The